Julie Rosenthal, MD, MS, discusses signs and symptoms of age-related macular degeneration as well as methods of treatment. Rosenthal: Some people don't have any symptoms at all when the disease is ...

It would be devastating to lose your eyesight to macular degeneration. Age-related macular degeneration (AMD) is a progressive eye disease that affects those over the age of 50. There is ...

Age-related macular degeneration (AMD) causes significant vision loss in seniors who have it. And there are many of them. This degenerative eye disease affects more than 500,000 Quebecers, about five ...

Airedale Opticians in Yorkshire introduced an age-related macular degeneration (AMD) clinic to its suite of services at the ...

Apellis Pharmaceuticals, Inc. ( APLS) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM EST ...

The only approved gene therapy for RP today targets a single gene RPE65, which accounts for just 1% to 2% of the total RP patient population. We believe OCU400 has significantly wider commercial ...

ORLANDO, Fla. (Ivanhoe Newswire) — There are two types of macular degeneration: dry and wet. Dry age-related macular degeneration is the most common type — it happens when small deposits form under ...

A widely used diabetes and weight-loss medicine is now under closer review after a large new study raised concerns about its ...

Please provide your email address to receive an email when new articles are posted on . The tyrosine kinase inhibitor maintained vision at week 36 in the SOL-1 trial. Axpaxli demonstrated positive ...

An Ocular Therapeutix drug developed for the wet form of age-related macular degeneration was better at helping patients maintain vision compared to a blockbuster Regeneron Pharmaceuticals drug that ...

A single injection of the tyrosine kinase inhibitor hydrogel has demonstrated superiority to aflibercept 2 mg in maintaining visual acuity and providing higher rescue-free rates through 1 year in ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% ...